NYSE:CBT - Cabot Stock Price, News & Analysis

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

Cabot declared a quarterly dividend on Friday, July 12th. Investors of record on Friday, August 30th will be paid a dividend of $0.35 per share on Friday, September 13th. This represents a $1.40 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend is Thursday, August 29th. View Cabot's Dividend History.

Cabot announced that its board has initiated a share buyback program on Monday, July 16th 2018, which allows the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 10.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.

Cabot Corp (NYSE:CBT) announced its quarterly earnings data on Monday, August, 5th. The specialty chemicals company reported $1.00 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $1.00. The specialty chemicals company had revenue of $845 million for the quarter, compared to analyst estimates of $858.86 million. Cabot had a net margin of 6.49% and a return on equity of 18.60%. The business's revenue was down 1.1% on a year-over-year basis. During the same period last year, the business earned $1.06 earnings per share. View Cabot's Earnings History.

Cabot is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Cabot.

4 brokers have issued 1 year price objectives for Cabot's stock. Their forecasts range from $40.00 to $76.00. On average, they expect Cabot's share price to reach $50.50 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Cabot.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cabot.

News stories about CBT stock have trended negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cabot earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the specialty chemicals company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Cabot.

Cabot saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 707,100 shares, a decrease of 10.3% from the July 31st total of 788,300 shares. Based on an average trading volume of 368,400 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.2% of the company's shares are sold short. View Cabot's Current Options Chain.

Some companies that are related to Cabot include Versum Materials (VSM), Platform Specialty Products (PAH), Element Solutions (ESI), WD-40 (WDFC), Orion Engineered Carbons (OEC), Advanced Emissions Solutions (ADES), Flotek Industries (FTK), Pure Bioscience (PURE), HighCom Global Security (HCGS), GlyEco (GLYE), Artemis Therapeutics (ATMS) and Ener-Core (ENCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabot investors own include Broadcom (AVGO), Energy Transfer LP Unit (ET), JPMorgan Chase & Co. (JPM), Oracle (ORCL), Adobe (ADBE), Gilead Sciences (GILD), AT&T (T), Wells Fargo & Co (WFC), Cisco Systems (CSCO) and Micron Technology (MU).

Cabot's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.20%), BlackRock Inc. (9.31%), Vanguard Group Inc. (8.93%), LSV Asset Management (4.78%), Bank of New York Mellon Corp (4.63%) and Earnest Partners LLC (4.07%). Company insiders that own Cabot stock include Brian A Berube, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Michael M Morrow, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Institutional Ownership Trends for Cabot.

CBT stock was sold by a variety of institutional investors in the last quarter, including Quest Capital Management Inc. ADV, BlackRock Inc., BlackRock Inc., Russell Investments Group Ltd., Grantham Mayo Van Otterloo & Co. LLC, Vanguard Group Inc., AQR Capital Management LLC and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Cabot.

CBT stock was acquired by a variety of institutional investors in the last quarter, including Earnest Partners LLC, Nuveen Asset Management LLC, Bank of America Corp DE, Royal Bank of Canada, Deprince Race & Zollo Inc., Wells Fargo & Company MN, WBI Investments Inc. and Icon Advisers Inc. Co.. View Insider Buying and Selling for Cabot.

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBT stock can currently be purchased for approximately $45.94.

Cabot has a market capitalization of $2.65 billion and generates $3.24 billion in revenue each year. The specialty chemicals company earns $-113,000,000.00 in net income (profit) each year or $4.03 on an earnings per share basis. Cabot employs 4,600 workers across the globe.View Additional Information About Cabot.

The official website for Cabot is http://www.cabot-corp.com/.

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at 617-345-0100 or via email at [email protected]